Correction: LabTech launches MicroStreak in US

By ALS staff
Friday, 13 June, 2008

In our online story LabTech launches MicroStreak in the US on June 11, we incorrectly stated that LabTech Systems had received royalties from sales.

The company is anticipating royalties but they have not been received yet. LabTech Systems has instead received licence payments of $4.9 million to date from licencee bioMerieux, and is entitled to receive up to a total of $11.2 million.

The original story has been corrected. We apologise for the error.

Related News

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Existing medicines could help treat deadly childhood dementia

Australian researchers have identified several existing TGA‑approved medicines that could help...

Statins reduce heart attack and stroke risk in older people

It has previously been unclear whether statins were effective in reducing heart attack and stroke...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd